tbuckley/cabot-search huggingface dataset:
Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening
Authors: Reinier G. S. Meester, Chyke A. Doubeni, Iris Lansdorp-Vogelaar, Christopher D. Jensen, Miriam P. van der Meulen, Theodore R. Levin, Virginia P. Quinn, Joanne E. Schottinger, Ann G. Zauber, Douglas A. Corley, Marjolein van Ballegooijen
Journal: JAMA (2015)

Colonoscopy is the most commonly used colorectal cancer screening test in the United States. Its quality, as measured by adenoma detection rates (ADRs), varies widely among physicians, with unknown consequences for the cost and benefits of screening programs.To estimate the lifetime benefits, complications, and costs of an initial colonoscopy screening program at different levels of adenoma detection.Microsimulation modeling with data from a community-based health care system on ADR variation and cancer risk among 57,588 patients examined by 136 physicians from 1998 through 2010.Using modeling, no screening was compared with screening initiation with colonoscopy according to ADR quintiles (averages 15.3%, quintile 1; 21.3%, quintile 2; 25.6%, quintile 3; 30.9%, quintile 4; and 38.7%, quintile 5) at ages 50, 60, and 70 years with appropriate surveillance of patients with adenoma.Estimated lifetime colorectal cancer incidence and mortality, number of colonoscopies, complications, and costs per 1000 patients, all discounted at 3% per year and including 95% confidence intervals from multiway probabilistic sensitivity analysis.In simulation modeling, among unscreened patients the lifetime risk of colorectal cancer incidence was 34.2 per 1000 (95% CI, 25.9-43.6) and risk of mortality was 13.4 per 1000 (95% CI, 10.0-17.6). Among screened patients, simulated lifetime incidence decreased with lower to higher ADRs (26.6; 95% CI, 20.0-34.3 for quintile 1 vs 12.5; 95% CI, 9.3-16.5 for quintile 5) as did mortality (5.7; 95% CI, 4.2-7.7 for quintile 1 vs 2.3; 95% CI, 1.7-3.1 for quintile 5). Compared with quintile 1, simulated lifetime incidence was on average 11.4% (95% CI, 10.3%-11.9%) lower for every 5 percentage-point increase of ADRs and for mortality, 12.8% (95% CI, 11.1%-13.7%) lower. Complications increased from 6.0 (95% CI, 4.0-8.5) of 2777 colonoscopies (95% CI, 2626-2943) in quintile 1 to 8.9 (95% CI, 6.1-12.0) complications of 3376 (95% CI, 3081-3681) colonoscopies in quintile 5. Estimated net screening costs were lower from quintile 1 (US $2.1 million, 95% CI, $1.8-$2.4 million) to quintile 5 (US $1.8 million, 95% CI, $1.3-$2.3 million) due to averted cancer treatment costs. Results were stable across sensitivity analyses.In this microsimulation modeling study, higher adenoma detection rates in screening colonoscopy were associated with lower lifetime risks of colorectal cancer and colorectal cancer mortality without being associated with higher overall costs. Future research is needed to assess whether increasing adenoma detection would be associated with improved patient outcomes.
Kadınlarda ve erkeklerde androgenetik alopesi ve kardiyovasküler risk faktörleri: Kıyaslayıcı bir çalışma
Authors: Salvador Arias-Santiago, María Teresa Gutiérrez-Salmerón, Luisa Castellote-Caballero, Agustín Buendía-Eisman ve Ramón Naranjo-Sintes
Journal: Journal of the American Academy of Dermatology (2010)
Abstract 21327: Successful Undersized Restrictive Annuloplasty for Chronic Mitral Regurgitation with Advanced Cardiomyopathy Does Not Induce Functional Mitral Stenosis
Authors: Satoshi Kainuma, Kazuhiro Taniguchi, Toru Kuratani, Takayoshi Ueno, Taichi Sakaguchi, Shigeru Miyagawa, Yasushi Yoshikawa, Takashi Yamauchi, Koji Takeda, Shunsuke Saito, Yasuhiro Shudo, Takahiro Higuchi, Sokichi Kamata, Daisuke Yoshioka, Takafumi Masai, Koichi Toda, Toshihiro Funatsu, Haruhiko Kondoh, Yoshiki Sawa
Journal: Circulation (2010)

Introduction:  It remains controversial whether an undersized restrictive mitral annuloplasty (URMA) for chronic mitral regurgitation, based on the concept of mitral annulus restriction, may cause functional mitral stenosis. Herein, we evaluated hemodynamic changes in left ventricular (LV) function and mitral valve performance after URMA.   Methods:  We studied 119 patients with reduced ejection fraction (   Results:  Clinical symptoms as shown by NYHA class improved from 3.2±0.5 to 1.5±0.6 (p   Conclusion:  URMA for chronic MR resulted in significant improvements in LV function and mitral valve performance in a majority of patients without causing significant mitral stenosis.
771. Adenovirus-Mediated siRNA Against Survivin Enhanced Sensitivity to Paclitaxel-Induced Apoptosis in MCF-7 Cells
Authors: Toshihiro Tanaka, Hiroaki Uchida, Katsunori Sasaki, Makoto Miyagishi, Kazunari Taira, Hirofumi Hamada
Journal: Molecular Therapy (2004)
The T-box transcription factor gene TBX22 is mutated in X-linked cleft palate and ankyloglossia
Authors: Claire Braybrook, Kit Doudney, Ana Carolina B. Marçano, Alfred Arnason, Arni Bjornsson, Michael A. Patton, Paul J. Goodfellow, Gudrun E. Moore, Philip Stanier
Journal: Nature Genetics (2001)
Pharmacokinetics, tissue distribution and anti-tumor activity of the Src/Abl kinase inhibitor AZD0530 in a rat xenograft model
Authors: Armelle Logie, Paul D. Martin, Elizabeth A. Partridge, Stephanie L. Byatt, Robin D. Whittaker, Tim P. Green
Journal: Cancer Research (2005)

5989   AZD0530 is a highly selective, dual-specific small molecule inhibitor of Src family kinases and Bcr-Abl. A series of studies were performed to characterize the distribution, pharmacokinetics and tumor growth inhibitory effects of AZD0530 in rats bearing Src 3T3 xenografts (3T3 mouse fibroblast transfected with a constitutively active human c-Src kinase in an overexpressing vector). Src 3T3 xenograft growth is driven by Src. In study 1, tumor growth inhibition was assessed at dose levels of 1, 3, 6 and 10 mg/kg/day (per os administration). AZD0530 produced a dose-related inhibition of tumor growth, with more than 90% of tumor growth inhibition at 6 and 10 mg/kg, 19% inhibition at 3 mg/kg and no effect at 1 mg/kg compared to a vehicle control group. In study 2, a single 10 mg/kg  [14] C-labeled dose of AZD0530 was administered per os to rats and tissue distribution assessed by quantitative whole body autoradiography. Drug-related material was extensively distributed to many tissues with high and protracted levels in the xenograft. The third study assessed the pharmacokinetics of AZD0530 in plasma and tumor following a 25 mg/kg single dose (per os administration). Maximum tumor levels of AZD0530 (∼44 μg/g) were approximately 40-fold higher than those in plasma. The shapes of the plasma and tumor AZD0530 concentration versus time curves were similar though the tumor curve lagged behind that of plasma. AZD0530 is in early clinical development.
Functional independence, symptoms, quality of life and emotional responses after pulmonary rehabilitation in COPD
Authors: Francesca Moretti, Guido Vagheggini, Stefano Mazzoleni, Giulia Montagnani, Eugenia Panait Vlad, Pier Paolo Cavicchioli, Giulia Farru, Luca Pantani, Daniele Berrighi, Lorenzo Buono, Nicolino Ambrosino
Journal: European Respiratory Journal (2014)

Background and aim: Functional independence Measure (FIM), has been recently included among the outcome measures of pulmonary rehabilitation (PR). Aim of the study was to analyze relationships between changes in FIM and quality of life after PR in COPD patients.

Materials and methods :We prospectively enrolled 55 COPD patients (26m; age 72.3±8.5years) consecutively undergoing an inpatient PR program after an episode of severe acute exacerbation between September 2012 to September 2013. Medical Research Council (MRC) dyspnea, FIM, Copd Assessment Test (CAT) and St. George's Respiratory Questionnaire (SRGQ), Beck Depression Inventory (BD) and State-Trait Anxiety Inventory (STAI) scores were assessed at admission and at the end of PR. The subjects were divided into two subgroups (SG1 and SG2) according to the median value (MV) of FIM change (SG1<, SG2≥MV).

Results : Four patients were excluded from data analysis (3 deceased, 1 transferred). After PR whole group improved in MRC (2.9±0.8 to 2.0±0.9; p=0.000), FIM (97.2±25.7 to 105.0±23.1; p=0.002) SGRQ (44.0±17.3 to 32.5±16.8; p=0.000), and CAT (19.0±7.0 to 14.5±6.0; p=0.000) scores, and in Six-minute walking distance (219.7±102.0m to 275.2±123.6m; p=0.000). FIM change MV was 6. SG1 and SG2 were homogeneous by age and gender. SG1 showed higher PaCO2 and HCO3, and lower FIM at pre-PR. No significant differences on quality of life (CAT, SGRQ) and emotional status were observed between SG1 and SG2, both at pre- and post-PR.

Conclusions : Improvement in functional independence is higher in patients more severely impaired in activities of daily living. Changes in FIM are not related to changes in perceived quality of life.
CURRENT TREATMENT OF TUBERCULOUS MENINGITIS: A PRELIMINARY REPORT
Authors: E J DES AUTELS, K H PFUETZE
Journal: Annals of Internal Medicine (1954)

ExcerptThe authors are reporting 16 consecutive cases of tuberculous meningitis started on treatment between June, 1952, and March, 1953. Five of the 16 patients also had miliary tuberculosis. All of these patients received streptomycin plus sodium para-aminosalicylic acid (sodium PAS) plus isoniazid.The purpose of this report is to suggest that patients with tuberculous meningitis respond quite favorably to current methods of treatment. A comparison of the survival rates among 63 patients with tuberculous meningitis, with and without miliary tuberculosis, treated on three different regimens, reveals substantial improvement during the past few years (table 1). Eight months after treatment was...
Oral contraceptives and myocardial infarction: results of the MICA case-control study Commentary: Oral contraceptives and myocardial infarction: reassuring new findings
Authors: N. Dunn, M. Thorogood, B. Faragher, L. de Caestecker, T. M MacDonald, C. McCollum, S. Thomas, R. Mann, O. Lidegaard
Journal: BMJ (1999)

<h3>Abstract</h3> <b>Objectives:</b>To determine the association between myocardial infarction and use of different types of oral contraception in young women. <b>Design:</b>Community based case-control study. Data from interviews and general practice records. <b>Setting:</b>England, Scotland, and Wales. <b>Participants:</b>Cases (n=448) were recruited from women aged between 16 and 44 who had suffered an incident myocardial infarction between 1 October 1993 and 16 October 1995. Controls (n=1728) were women without a diagnosis of myocardial infarction matched for age and general practice. <b>Main outcome measures:</b>Odds ratios for myocardial infarction in current users of all combined oral contraceptives stratified by their progestagen content compared with non-users; current users of third generation versus second generation oral contraceptives. <b>Results:</b>The adjusted odds ratio for myocardial infarction was 1.40 (95% confidence interval 0.78 to 2.52) for all combined oral contraceptive users, 1.10 (0.52 to 2.30) for second generation users, and 1.96 (0.87 to 4.39) for third generation users. Subgroup analysis by progestagen content did not show any significant difference from 1, and there was no effect of duration of use. The adjusted odds ratio for third generation users versus second generation users was 1.78 (0.66 to 4.83). 87% of cases were not exposed to an oral contraceptive, and 88% had clinical cardiovascular risk factors or were smokers, or both. Smoking was strongly associated with myocardial infarction: adjusted odds ratio 12.5 (7.29 to 21.5) for smoking 20 or more cigarettes a day. <b>Conclusions:</b>There was no significant association between the use of oral contraceptives and myocardial infarction. The modest and non-significant point estimates for this association have wide confidence intervals. There was no significant difference between second and third generation products.
Transvenous phrenic nerve stimulation improves Cheyne-Stokes respiration in patients with chronic heart failure
Authors: Xilong Zhang, Ning Ding, Shijiang Zhang, Bin Yang
Journal: European Respiratory Journal (2011)

Background:  Cheyne-Stokes respiration (CSR) may accelerate progression of congestive heart failure (CHF) and is associated with poor survival. Phrenic nerve stimulation (PNS) may interrupt CSR and improve CHF outcomes. We report the first clinical use of transvenous PNS in CHF patients with CSR.   Methods:  23 CHF patients with central sleep apnea and CSR were enrolled. A single stimulation lead was placed at the junction between the superior vena cava and brachiocephalic vein or in the left pericardiophrenic vein. PNS stimulation was performed using the Eupnea System software. Respiratory properties were assessed prior to and post-PNS. PNS was assessed at a maximum of 10 mA.   Results:  No adverse events were seen under maximum normal stimulation parameters for a maximum single 12 hour sleep cycle. Phrenic nerve stimulation was able to reproducibly slow the rate of breathing in a predictable manner and raise end-tidal expiratory CO 2 . When PNS was applied following a series of central sleep apneic events, a trend towards stabilization of breathing and heart rate, as well as improvement in oxygen saturation, was seen.There was a significant improvement in indices of apnea/hypopnea, central apnea, oxygen saturation and sleep efficiency after PNS versus pre-PNS (all  P     Conclusion:  Unilateral transvenous PNS proved to be a safe and feasible treatment and by effectively improving CSR.
Abstract 11137: Nitroglycerine-Induced Vasodilation Was Significantly Smaller in Peripheral Artery Diesase-Patients With Critical Limb Ischemia Compared With Those Without
Authors: Tatsuya Maruhashi, Yukihito Higashi, Ayumu Nakashima, Takeshi Matsumoto, Nozomu Oda, Yumiko Iwamoto, Akimichi Iwamoto, Masato Kajikawa, Kensuke Noma, Yasuki Kihara
Journal: Circulation (2014)

Introduction: Nitroglycerine-induced vasodilation is usually used as a control test for flow-mediated vasodilation (FMD). However, nitroglycerine-induced vasodilation per se has also been reported to be impaired in patients with atherosclerosis. The purpose of this study was to determine the relationship between nitroglycerine-induced vasodilation and the clinical severity of peripheral artery disease (PAD). Methods: We measured nitroglycerine-induced vasodilation and FMD in 144 subjects (mean age: 63.8±15.1 years), including 32 PAD patients with critical limb ischemia (CLI group), 28 PAD patients without CLI (non-CLI group), 60 age- and sex-matched patients without established cardiovascular disease (at-risk group), and 24 healthy subjects (healthy group). Results: Nitroglycerine-induced vasodilation was significantly impaired in the CLI group compared to that in the other three groups (healthy group, 16.0±5.3%; at-risk group, 12.9±3.8%; non-CLI group, 10.3±5.1%; CLI group, 6.7±3.9%; P<0.05, respectively...
A New Cytokine-Dependent Monoblastic Cell Line With t(9;11)(p22;q23) Differentiates to Macrophages With Macrophage Colony-Stimulating Factor (M-CSF) and to Osteoclast-Like Cells With M-CSF and Interleukin-4
Authors: Takashi Ikeda, Kazunori Sasaki, Kazuma Ikeda, Genji Yamaoka, Koichi Kawanishi, Yasunori Kawachi, Tatsumi Uchida, Jiro Takahara, Shozo Irino
Journal: Blood (1998)
Switching biologics for psoriasis
Authors: Anthony D. Ormerod
Journal: British Journal of Dermatology (2010)

Journal Article Switching biologics for psoriasis Get access Anthony D. Ormerod Anthony D. Ormerod Department of Applied Medicine, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZN, U.K. E‐mail: a.d.ormerod@abdn.ac.uk Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 163, Issue 4, 1 October 2010, Pages 667–669, https://doi.org/10.1111/j.1365-2133.2010.09999.x Published: 01 October 2010
THE ACID-BASE EQUILIBRIUM IN PATHOLOGICAL CONDITIONS
Authors: Edward Muntwyler, Charles T. Way, Dorothy Binns
Journal: Journal of Clinical Investigation (1931)

Nephritis with nitrogen retention has generally been considered to be associated with a progressive acidosis.Whitney (1) and Chace and Myers (2) were among the first to point this out.The latter workers observed that all fatal cases of chronic nephritis with marked nitrogen retention showed a severe acidosis, sufficient in many in- stances to be the actual cause of death.Since acidosis is a term applied to conditions in which the bicarbonate concentration of the blood is low, it may arise from several causes: a reduction of the total base concentration or an increase of the acid ions.An influx of acid into the blood may occur from an abnormal formation as in diabetes mellitus or from a decreased elimination as in chronic nephritis.Marriott and Howland (3) demonstrated an increase in the phosphate of the serum in nephritis with a lowered CO2 capacity of the plasma and decrease in plasma pH.Greenwald (4), Denis and Minot (5), Salvesen and Linder (6), and Schmitz, Rohdenburg and Myers (7) 1 This investigation was aided by a grant from the Josiah Macy, Jr., Foundation.
Abstract #LB-275: KLF8 promotes human breast cancer invasion by trans-activating MMP9
Authors: Jihe Zhao
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Kruppel-like factor 8 (KLF8) is a transcription factor that we previously identified as a downstream target of FAK in the cell cycle regulation and is up-regulated in human breast and ovarian cancer cells and tumor tissues. We have recently showed that overexpression of KLF8 in human breast epithelial MCF-10A cell promotes the epithelial-mesenchymal transition (EMT) and the acquisition of invasive phenotype. In this study, we report that inducible expression of KLF8 is associated with an increase in the promoter activity and expression of the matrix metalloproteinase 9 (MMP9). We show that inducible expression of KLF8 significantly increased the mRNA expression level of MMP9 as well as the activity of MMP9 in the condition medium. Furthermore, we show that the MMP inhibitor GM6001can decrease the invasive capability of MCF-10A expressing inducible KLF8 using Matrigel invasion assay. Using promoter luciferase reporter assays, we demonstrate that KLF8 strongly promotes the activity of MMP9 promoter in MCF-10A cells. The knockdown of KLF8 by inducible shRNA decreases MMP9 expression and the MMP9 activity in condition medium as well as the cell invasion in metastatic breast cancer cell line MDA-MB-231 cells. In 3D culture, induction of KLF8 expression can disrupt the normal acinus phenotypes of MCF-10A cell, which can be partially rescued by GM6001. Conversely, knockdown of KLF8 or GM6001 treatment can prevent the malignant morphology formation of MDA-MB-321 cells. Taken together, these results highlight a novel role for KLF8 in the activation of MMP9 transcription and breast cancer cell invasion. Experiments are in progress to determine the in vivo role of KLF8 for breast cancer invasion and metastasis using a xenograft mouse model of human breast cancer.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-275.
A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease
Authors: Kristina Bečanović, Anne Nørremølle, Scott J Neal, Chris Kay, Jennifer A Collins, David Arenillas, Tobias Lilja, Giulia Gaudenzi, Shiana Manoharan, Crystal N Doty, Jessalyn Beck, Nayana Lahiri, Elodie Portales-Casamar, Simon C Warby, Colúm Connolly, Rebecca A G De Souza, Sarah J Tabrizi, Ola Hermanson, Douglas R Langbehn, Michael R Hayden, Wyeth W Wasserman, Blair R Leavitt
Journal: Nature Neuroscience (2015)
Abstract P232: The Relationship Between Lifestyle Factors and Cardiovascular Disease Risk in Hiv+ Adults
Authors: Allison R Webel, Abdus Sattar, Chris T Longenecker, Nathanial J Schreiner, Richard Josephson
Journal: Circulation (2015)

Introduction:  HIV+ adults used to have markedly decreased life expectancy. Now, HIV is a manageable chronic disease and HIV+ adults are at risk for clinical CVD due to multiple physiological risk factors. Lifestyle factors may contribute to this risk and yet little is known about the influence of exercise, stress, and medication adherence on the CVD risk in HIV+ adults. Therefore, we sought to examine the associations over time among exercise, stress, medication adherence and CVD risk and hypothesized that they would be associated with the 30-year predicted risk of developing CVD in HIV+ adults.   Methods:  Seventy HIV+ adults taking antiretroviral therapy (ART) were enrolled. Participants completed anthropomorphic measures, one-week exercise diary, Perceived Stress Scale, and consented to medical chart abstraction. Participants returned in one year and completed the same assessments. Cardiovascular risk was calculated using the Framingham 30-year risk models. We used generalized estimating equations to evaluate the association between lifestyle factors and CVD risk.   Results:  Participant’s average age at baseline was 48.6 ± 8.4 years, 35 (50%) were male, 58 (83%) were African-American. At baseline, participants exercised 5.0 ± 5.7 hours per week, had a perceived stress scale score of 17.8, and were adherent to ART. One year later they exercised 7.3 ± 6.4 hours per week, had an average perceived stress scale score of 17.3, and were adherent to ART. Using data from two time points exercise, stress, and medication adherence were associated with 30-year lipid-based (Wald χ 2  =9.5, p=0.02) and 30-year BMI-based (Wald χ 2  =14.2, p   Conclusion:  Lifestyle factors are significantly associated with CVD risk in HIV+ adults. Perceived stress was negatively associated with CVD risk with indicating that as stress increased, CVD risk decreased. This surprising finding indicates that more work is necessary to better understand the relationship between lifestyle factors and cardiovascular disease risk in HIV+ adults.